The initiation of coverage by Wells Fargo with an Equal-Weight rating suggests a neutral outlook on Myriad Genetics' stock, indicating that the stock is properly valued at its current price. The price target of $20 provides a benchmark for investors but does not imply significant upside or downside, hence the neutral score. The relevance is high as the news is directly about Myriad Genetics. The importance is significant as analyst ratings can influence market perception and investment decisions. The confidence level is high due to the straightforward nature of analyst coverage initiations.